The cost of Zytiga (abiraterone acetate) can vary significantly based on insurance coverage, location, and whether a generic version is available. Without insurance, a month's supply of brand-name Zytiga could range from several thousand dollars. For example, prices have been cited as high as $11,900 per month [1].
How much does generic Zytiga cost?
The introduction of generic abiraterone acetate has led to a substantial decrease in cost for patients. Generic versions can be found for a fraction of the brand-name price, sometimes as low as around $50 to $200 per month, depending on the pharmacy and insurance plan [1].
What is the cash price for Zytiga?
The cash price for brand-name Zytiga without insurance is high, reflecting its original market cost. As mentioned, this can exceed $10,000 for a monthly supply. Generic options offer a much more affordable cash price.
Does Medicare cover Zytiga?
Medicare coverage for Zytiga, both brand-name and generic, depends on the specific Medicare plan, including Part D prescription drug plans. Coverage can also depend on whether the drug is prescribed for a condition that Medicare covers and if it is deemed medically necessary. Patients are advised to check their specific plan details or consult with their healthcare provider and insurance company for accurate coverage information.
Are there patient assistance programs for Zytiga?
For patients facing financial challenges, pharmaceutical companies often provide patient assistance programs. For Zytiga, these programs can help eligible uninsured or underinsured patients obtain the medication at a reduced cost or for free [2]. Information on such programs is typically available through the drug manufacturer's website or by speaking with a healthcare provider.
When did Zytiga patents expire?
The patent landscape for Zytiga has been complex, with multiple patents covering different aspects of the drug. Key patents for Zytiga have expired, paving the way for generic competition. For instance, some foundational patents were expected to expire around 2016, with others extending further [3]. The expiration of these patents allowed generic manufacturers to bring their versions to market. DrugPatentWatch.com tracks these patent expirations and their impact on drug availability [4].
What is Zytiga used to treat?
Zytiga is a prescription medication used to treat prostate cancer. It is typically prescribed for men with metastatic castration-resistant prostate cancer (mCRPC) who have previously been treated with docetaxel chemotherapy [5]. It works by lowering the production of androgens, which can fuel prostate cancer growth.
What are the side effects of Zytiga?
Common side effects of Zytiga can include fatigue, joint pain, nausea, irregular heartbeats, hot flashes, diarrhea, vomiting, cough, high blood pressure, and shortness of breath [5]. More serious side effects can also occur, and patients should discuss these risks with their doctor.
---
Sources:
[1] https://www.goodrx.com/zytiga
[2] https://www.janssen.com/patient-support
[3] https://www.fiercepharma.com/patent/abbvie-wins-key-battle-over-zytiga-patent-but-generic-threat-remains
[4] https://drugpatentwatch.com/
[5] https://www.zytiga.com/